Advertisement
Advertisement
ARWR
Arrowhead Research Corporation
61.04
USDSponsored
-1.88
-2.99%
Apr 02, 15:59 UTC -4
Closed
After-Market
61.28
+0.24
+0.39%
ARWR Earnings Reports
Positive Surprise Ratio
ARWR beat 12 of 40 last estimates.
30%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$77.20M
/-$1.21
Implied change from Q1 26 (Revenue/ EPS)
-70.76%
/-650.00%
Implied change from Q2 25 (Revenue/ EPS)
-85.78%
/-144.00%
Arrowhead Research Corporation earnings per share and revenue
On Feb 05, 2026, ARWR reported earnings of 0.22 USD per share (EPS) for Q1 26, missing the estimate of 0.25 USD, resulting in a -14.76% surprise. Revenue reached 264.03 million, compared to an expected 275.47 million, with a -4.15% difference. The market reacted with a -0.19% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 13 analysts forecast an EPS of -1.21 USD, with revenue projected to reach 77.20 million USD, implying an decrease of -650.00% EPS, and decrease of -70.76% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Palvella Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.92
Actual
-$1.07
Surprise
-15.20%
Forte Biosciences, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.23
Actual
-$1.39
Surprise
-12.31%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.44
Actual
-$1.91
Surprise
-32.66%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Fortress Biotech, Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.11
Actual
-$0.01
Surprise
-108.91%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Tvardi Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.65
Actual
-$0.78
Surprise
-18.33%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
FAQ
What were Arrowhead Research Corporation's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Arrowhead Research Corporation reported EPS of $0.22, missing estimates by -14.76%, and revenue of $264.03M, -4.15% below expectations.
How did the market react to Arrowhead Research Corporation's Q1 2026 earnings?
The stock price moved down -0.19%, changed from $64.64 before the earnings release to $64.52 the day after.
When is Arrowhead Research Corporation expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Arrowhead Research Corporation's next earnings report?
Based on 13
analysts, Arrowhead Research Corporation is expected to report EPS of -$1.21 and revenue of $77.20M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement